KirinKirin Holdings Company, Limited2503東証プライム食料品FY ending Dec 2025, consolidated, IFRS

Kirin FY ending Dec 2025 results

About 44% of Kirin's sales come from Alcoholic Beverages, with Non-Alcoholic Beverages and Pharmaceuticals making up much of the rest.

Out of every ¥100 of sales, about ¥9 is left as operating profit.

Revenue changed +4.1% from the prior year, operating profit +67.3%.

Revenue and profit pattern

Revenue and profit upProfit grew faster

Revenue +4.1% · profit +67.3%, calculated from disclosed figures.

Operating leverage: 16.57× (profit growth ÷ revenue growth)

What changed from last year

FY ending Dec 2024 → FY ending Dec 2025

Revenue: +4.1%¥2.34T → ¥2.43T
Gross profit: +8.6%¥1.07T → ¥1.16T
Operating income: +67.3%¥125.3B → ¥209.7B
Net income attributable to owners: +153.4%¥58.2B → ¥147.5B
Operating cash flow: +21.7%¥242.8B → ¥295.4B
Free cash flow: +92.5%¥62.3B → ¥119.8B

Results at a glance

Revenue for the FY ending Dec 2025 was ¥2.43T, up +4.1% from ¥2.34T.
Operating income rose +67.3% from ¥125.3B to ¥209.7B, and net income attributable to owners climbed +153.4% from ¥58.2B to ¥147.5B.
Operating cash flow grew +21.7% to ¥295.4B, and free cash flow rose +92.5% to ¥119.8B.

What drove the change

A full year of FANCL, plus the sale of Kyowa Hakko Bio's amino acid business, turned the health science business profitable
In Japan, beer volumes fell, but price increases, a reworked brand mix and tight cost control lifted profit
In pharmaceuticals, Crysvita and Poteligeo kept growing, so sales and profit rose despite currency effects and Japanese drug price cuts
Losses booked in the prior year, from a step acquisition and an impairment on an equity-method investment, did not recur

Things to watch

Higher raw material and fuel prices could push up production costs
Tighter rules on selling and advertising alcohol around the world could reduce drinking
Healthcare cost controls in Japan and abroad could force drug price cuts and speed the shift to generics

Annual securities report: Management's discussion and analysis / 経営者による財政状態、経営成績及びキャッシュ・フローの状況の分析 · Annual securities report: Business risks / 事業等のリスク

Where the money goes

FY ending Dec 2024 → FY ending Dec 2025

Where ¥100 of sales goes

For every ¥100 Kirin sells, how much goes where, and how much is kept.

FY ending Dec 2025

Cost of sales: ¥52
SG&A: ¥37
Other costs: ¥2
Operating profit: ¥9
Net profit kept: ¥6

Annual margin trends

Gross margin47.6%

Operating margin8.6%

Net margin6.1%

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Which businesses earn the money

Revenue by business segment, and the profit each one keeps.

FY ending Dec 2025

Alcoholic Beverages¥1.08T
44%
Op. margin 12.6%Industry: Alcoholic Beverages
Non-Alcoholic Beverages¥578.2B
24%
Op. margin 11.7%Industry: Beverages & Dairy
Pharmaceuticals¥496.5B
20%
Op. margin 20.6%Industry: Pharmaceuticals
Health Science¥251.4B
10%
Op. margin 4.4%Industry: Cosmetics
Other¥32B
1%
Op. margin -3.4%

Profit by segment

※ Segment figures include inter-segment sales and do not sum to the company total

Sources

Show source documents (6)

EDINET (FSA Japan)
訂正有価証券報告書－第187期(2025/01/01－2025/12/31)
ID S100YT3M2026-08-03Open
EDINET (FSA Japan)
有価証券報告書－第186期(2024/01/01－2024/12/31)
ID S100VH7L2025-03-28Open
EDINET (FSA Japan)
有価証券報告書－第185期(2023/01/01－2023/12/31)
ID S100T4MO2024-03-28Open
EDINET (FSA Japan)
有価証券報告書－第184期(2022/01/01－2022/12/31)
ID S100QFXL2023-03-30Open
EDINET (FSA Japan)
有価証券報告書－第183期(令和3年1月1日－令和3年12月31日)
ID S100NR8P2022-03-30Open
EDINET (FSA Japan)
有価証券報告書－第182期(令和2年1月1日－令和2年12月31日)
ID S100L1A82021-03-30Open

Extracted from XBRL: 45 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open Markdown Share on X Save image